Puruite Pharmaceutical

Puruite Pharmaceutical is a clinical-stage specialty pharmaceutical company headquartered in Zhejiang, China, dedicated to the development of advanced inhalation therapies for respiratory conditions. The company focuses on complex formulations and delivery devices, including metered-dose inhalers (MDI), dry powder inhalers (DPI), and nasal sprays. Its pipeline features a range of generic and innovative combination therapies targeting asthma and chronic obstructive pulmonary disease (COPD). Puruite maintains integrated R&D and large-scale GMP manufacturing capabilities to ensure the quality and accessibility of its respiratory products. By leveraging its proprietary inhalation technology platform, the company aims to address the significant unmet need for high-quality respiratory treatments in the Chinese market.